SLC39A8-CDG is a rare inherited condition that usually becomes clear in infancy or early childhood. It can affect brain and body development, and common features include low muscle tone, delayed milestones, seizures, movement problems, and sometimes hearing loss or poor growth. Not everyone will have the same experience. SLC39A8-CDG is lifelong, and severe cases can be life-threatening, especially when neurologic problems are serious. Treatment focuses on supportive care, and some people with SLC39A8-CDG may benefit from carefully monitored manganese treatment, so early signs of SLC39A8-CDG should be assessed by a specialist.
How many people live with Slc39a8-cdg?
SLC39A8-CDG is thought to be extremely rare, with fewer than about 8,100 people worldwide (Orphanet, 2024) and fewer than about 340 people in the United States (Orphanet, 2024). These numbers are based on Orphanet placing the condition in the “fewer than 1 in 1,000,000” group, so they are rough upper-limit estimates rather than direct counts.
Overview
Slc39a8-cdgSymptoms
SLC39A8-CDG often causes low muscle tone, developmental delay, poor coordination, and movement problems. Many children also have short stature, feeding difficulties, seizures, and distinctive facial features, though signs can vary widely.
Outlook and prognosis
Outlook in SLC39A8-CDG varies with severity and how early treatment begins. Many living with SLC39A8-CDG do best with early manganese treatment, which can improve movement, seizures, and development. Lifelong follow-up is usually needed.
Causes and risk factors
SLC39A8-CDG is caused by harmful changes in the SLC39A8 gene, usually inherited from both parents, though severity can vary. Risk is highest with a family history or carrier parents; lifestyle or environmental factors do not cause it.
Genetic influences
Genetics are central to Slc39a8-cdg, because it is caused by changes in the SLC39A8 gene. These genetic variations affect how the body handles manganese, and the exact change can influence how severe Slc39a8-cdg is.
Diagnosis
Diagnosis of SLC39A8-CDG usually starts with clinical features, blood and urine tests, and brain imaging. Doctors confirm the genetic diagnosis of SLC39A8-CDG with genetic testing.
Treatment and drugs
Treatment for SLC39A8-CDG often centers on carefully supervised manganese supplements, which can improve movement, muscle tone, seizures, and development in some children. Many also need therapies and regular checks for growth, liver health, and side effects.
Symptoms
Many children with SLC39A8-CDG first come to attention because everyday skills take more time to develop, feeding is hard, or movement seems unusual. The early features of SLC39A8-CDG can include low muscle tone, delayed milestones, seizures, and trouble with growth, speech, hearing, or vision. Features can vary from person to person and may change over time.
Babies and children may take longer than expected to hold up their head, sit, crawl, stand, or walk. For many families, this shows up as needing extra help with movement and daily activities.
Low muscle tone can make a baby feel floppy and can make it harder to hold the head steady, sit upright, or feed well. As children grow, they may tire more easily and need support from physical therapy or mobility aids.
Many people with SLC39A8-CDG have unusual movements such as stiffness, twisting, tremor, or poor coordination. This can make walking, reaching for things, or keeping balance more difficult.
Speech is often delayed, and some children use only a few words or rely on gestures or communication devices. Learning difficulties are common, but how much they affect daily life can differ from child to child.
How people usually first notice Slc39a8-cdg?
How SLC39A8-CDG is first noticed often depends on the child, but the first signs of SLC39A8-CDG usually appear in infancy or early childhood when a baby seems unusually floppy, misses expected movement milestones, or has feeding problems and slow growth. Families or doctors may also notice developmental delay, low muscle tone, seizures, or unusual movements, and some children have hearing loss, vision problems, or differences in the shape of the skull, eyes, or limbs that prompt a genetics evaluation. Because this condition can look different from one child to another, diagnosis often begins when these early patterns appear together rather than from one single warning sign.
Types of Slc39a8-cdg
No distinct types of Slc39a8-cdg are widely recognized.
Can I slow down the onset of symptoms?
For SLC39A8-CDG, there is no good evidence that lifestyle changes like diet, exercise, sleep, or mental activity can meaningfully delay when symptoms begin, because this is a rare inherited condition that is mainly driven by the gene change itself. What may help is very early diagnosis and treatment by a specialist team, especially careful manganese replacement, which has improved symptoms in some reported children, but that is not the same as preventing the condition and it may not stop symptoms from appearing. Even so, getting expert care early can still make a real difference in how problems are recognized and managed over time.
What genetics can tell you about symptoms
In SLC39A8-CDG, the exact changes in both copies of the SLC39A8 gene can help explain why symptoms vary so much from one person to another. Some genetic changes are linked with earlier onset and more severe problems, such as significant developmental delay, low muscle tone, seizures, movement difficulties, and poor growth, while others may cause a milder pattern. Even so, genetics does not predict everything, and people with the same condition can still have different symptoms and levels of day-to-day impact.
Causes and risk factors
People living with SLC39A8-CDG are born with it because both copies of the SLC39A8 gene have a harmful change. This gene helps move manganese in the body, and too little manganese can disrupt many normal body processes, including how proteins are built and used. The main risk factor for SLC39A8-CDG is having two carrier parents, so family history and related parents can raise the chance in a pregnancy. Diet, infections, and other health conditions do not cause SLC39A8-CDG, but they may affect how strongly symptoms show up over time. Genetic testing can sometimes clarify your personal risk.
What are the most common causes or risk factors?
SLC39A8-CDG is caused by changes in the SLC39A8 gene, and it usually happens only when a child inherits one changed copy of the gene from each parent. The main risk factors are a family history of the condition, having two carrier parents who do not have symptoms themselves, and parents who are related to each other, because they are more likely to carry the same rare gene change. There are no known lifestyle, diet, or environmental risk factors for this condition.
Environmental and biological risk factors
For SLC39A8-CDG, there are no well-established environmental or non-genetic biological risk factors known to increase the chance of the condition occurring. Awareness of both biological and environmental influences helps you feel prepared, but for this condition, pregnancy exposures, maternal health problems, and birth events have not been shown to be reliable risk factors. Most reported cases are not linked to anything a parent did or did not do during pregnancy.
No clear environmental, maternal health, or birth-related factors have been shown to raise the chance of SLC39A8-CDG. Researchers have not identified a consistent pattern involving infections, medications, pollution, delivery complications, or other outside exposures.
Genetic risk factors
When a baby or child has feeding, movement, or developmental problems linked to SLC39A8-CDG, families often want to know why it happened. For the genetic causes of SLC39A8-CDG, the key issue is usually an inherited change in the SLC39A8 gene. Most people with this condition have two harmful gene changes, one passed down from each parent. That is why carrier status and family history matter so much when thinking about risk in future pregnancies.
SLC39A8 changes: SLC39A8-CDG happens when both copies of the SLC39A8 gene have harmful changes. This gene helps move manganese into cells, so changes in it can disrupt the body’s normal use of manganese and the way sugar chains are added to proteins.
Recessive pattern: SLC39A8-CDG is inherited in an autosomal recessive pattern, which means a child usually needs one changed copy from each parent. Carrying a genetic change doesn’t guarantee the condition will appear, because people with one changed copy are usually healthy carriers.
Carrier parents: When both parents carry an SLC39A8 change, each pregnancy has a 25% chance of SLC39A8-CDG, a 50% chance of carrier status, and a 25% chance of inheriting neither changed copy. These chances are the same in every pregnancy.
Family history: Having a child, brother, or sister with SLC39A8-CDG makes it more likely that close relatives may also carry the same gene change. If both parents are carriers, future children have the same 25% chance of being affected.
Related parents: SLC39A8-CDG can be more likely when parents are biologically related, such as cousins, because they have a higher chance of carrying the same rare SLC39A8 change. This raises the risk for recessive conditions, although it does not mean a child will definitely be affected.
Lifestyle risk factors
SLC39A8-CDG is an inherited condition, so lifestyle habits do not cause it. Still, how lifestyle affects SLC39A8-CDG can matter for day-to-day symptoms, growth, strength, mobility, and complication risk. The most useful lifestyle risk factors for SLC39A8-CDG are the ones that influence nutrition, physical function, bone health, and safety.
Poor calorie, protein, or micronutrient intake can worsen growth problems, low muscle mass, fatigue, and recovery in people with SLC39A8-CDG. Regular nutrition support may help maintain strength and support overall function, especially when feeding is difficult.
Long meals, unsafe swallowing, or inconsistent feeding routines can raise the risk of dehydration, aspiration, and inadequate weight gain. Early feeding therapy and practical meal adjustments may reduce these complications and improve daily energy.
Too little movement can lead to worsening weakness, low endurance, joint stiffness, and loss of motor skills. Individualized activity and physiotherapy may help preserve mobility, balance, and participation while avoiding overexertion.
Low weight-bearing activity combined with poor calcium or vitamin D intake can increase the risk of low bone density and fractures if bone fragility is present. Safe exercise and attention to nutrition can support skeletal health and reduce injury risk.
Risk prevention
With SLC39A8-CDG, true prevention of the inherited condition itself is not possible because it is present from birth. In practice, prevention means lowering the chance of complications and supporting growth, movement, and day-to-day health as early as possible. Some prevention is universal, others are tailored to people with specific risks. Because this condition is rare and can affect several body systems, regular specialist follow-up matters.
Finding SLC39A8-CDG early can help treatment start sooner and may reduce the impact of some problems over time. This can be especially important when early symptoms of SLC39A8-CDG include low muscle tone, feeding trouble, or developmental delays.
Some people with SLC39A8-CDG may benefit from condition-specific treatment such as manganese supplements, but this must be prescribed and monitored by an experienced specialist. Taking manganese on your own can be unsafe, so dosing and blood tests are important.
Good nutrition can help support growth, strength, and overall health in people with SLC39A8-CDG. If chewing, swallowing, or weight gain is difficult, a feeding team or dietitian may help prevent undernutrition and dehydration.
Physical, occupational, and speech therapy can help protect function and make daily life easier. For many, this can mean safer walking, better posture, and support with communication or feeding skills.
Can you prevent Slc39a8-cdg?
No, SLC39A8-CDG cannot usually be prevented because it is a rare inherited condition caused by changes in a gene that are present from birth. If this condition runs in your family, meeting with a genetics specialist before pregnancy may help you understand the chances in a future child and talk through testing options, but it cannot guarantee prevention.
Transmission
SLC39A8-CDG is not infectious, so it does not spread from person to person through coughing, touch, blood, food, or sexual contact. Instead, the genetic transmission of SLC39A8-CDG happens when a child inherits two nonworking copies of the SLC39A8 gene, usually one from each parent.
This pattern is called autosomal recessive inheritance. In families where both parents are carriers, each pregnancy has a 1 in 4 chance of resulting in a child with SLC39A8-CDG, while carriers themselves often have no symptoms.
When to test your genes
Consider genetic testing as soon as a baby or child has unexplained low muscle tone, developmental delay, seizures, movement problems, hearing loss, or short stature, especially if several occur together. Early confirmation of SLC39A8-CDG can guide monitoring and may help tailor treatment, including checking manganese status.
Diagnosis
SLC39A8-CDG is usually suspected when a baby or child has a mix of developmental delays, low muscle tone, movement problems, seizures, or growth and feeding difficulties. The diagnosis of SLC39A8-CDG often starts with these clinical features and is then confirmed with specialized lab and genetic tests. Getting a diagnosis is often a turning point toward answers and support.
Doctors first look at the overall pattern of symptoms, including delayed milestones, floppy muscles, coordination problems, and sometimes hearing or vision concerns. Because these signs can overlap with other rare conditions, the full health history and physical exam are an important starting point.
Blood tests may show abnormal transferrin glycosylation, a clue that the body is not attaching sugars to proteins in the usual way. This is a key screening test for many congenital disorders of glycosylation, although follow-up testing is still needed.
A genetic test can confirm changes in the SLC39A8 gene and establish the genetic diagnosis of SLC39A8-CDG. Testing may be done with a targeted gene panel, exome sequencing, or another broad DNA test, especially when the diagnosis is not obvious at first.
Since SLC39A8 helps move manganese in the body, doctors may check manganese levels in blood. Low levels can support the diagnosis, although results need to be interpreted alongside symptoms and genetic findings.
How is Slc39a8-cdg diagnosed?
Doctors usually suspect SLC39A8-CDG from a child’s pattern of health problems, such as delayed development, low muscle tone, seizures, movement problems, and sometimes hearing loss or poor growth. Blood tests can then look for unusual sugar patterns on certain proteins and may also show low levels of manganese, a mineral the body needs, which can point toward this condition. The diagnosis is usually confirmed with genetic testing that finds harmful changes in both copies of the SLC39A8 gene.
Stages of Slc39a8-cdg
Slc39a8-cdg does not have defined progression stages. This rare genetic condition does not usually follow a standard step-by-step course, and symptoms can vary a lot from one person to another from infancy onward. Doctors usually start with a conversation about development, feeding, movement, seizures, and other early symptoms of Slc39a8-cdg, then use blood tests, brain imaging, and genetic testing to confirm the cause. Follow-up usually focuses on tracking growth, development, neurologic symptoms, and how well treatments and supportive therapies are helping over time.
Outlook and prognosis
The outlook for people with SLC39A8-CDG is highly variable and depends on how early the condition is recognized, how severe the neurologic and systemic involvement is, and whether treatment such as manganese supplementation is started promptly. Some affected children show meaningful improvement in development, muscle tone, seizures, movement abnormalities, and biochemical markers after treatment, especially when therapy begins early, but many continue to have lasting developmental and motor challenges. Reported complications can include severe epilepsy, feeding problems, dystonia, and progressive disability, which can substantially affect quality of life. Because SLC39A8-CDG is very rare and long-term follow-up data are limited, it is difficult to predict life expectancy with confidence for any individual patient. Mortality data are sparse, but severe presentations in infancy or early childhood can be life-threatening, particularly when neurologic disease and multisystem complications are profound.
Long-term effects
For many living with SLC39A8-CDG, the long-term picture depends on how severely the brain, muscles, hearing, and growth are affected early in life. Many continue to have developmental and movement-related challenges into childhood and adulthood, although the pattern can vary widely from one person to another. It’s important to remember that long-term doesn’t always mean progressive, and some features may stay fairly stable over time while others become more noticeable as daily demands increase.
Many people with SLC39A8-CDG have lasting delays in speech, learning, and everyday skills. In some, these differences remain mild, while others need significant support through childhood and adult life.
Low muscle tone, poor coordination, and involuntary movements can remain long term in SLC39A8-CDG. As children grow, this may affect walking, balance, handwriting, or tasks like feeding and dressing.
Some people with SLC39A8-CDG have seizures that continue over time or return after a quiet period. Early symptoms of SLC39A8-CDG can include seizures in infancy, and long-term effects may include an ongoing need for monitoring because seizure patterns differ widely.
Slow growth and short stature can be part of the long-term effects of SLC39A8-CDG. Some may also have lasting feeding difficulties or low weight, especially if eating has been hard since infancy.
How is it to live with Slc39a8-cdg?
Living with SLC39A8-CDG often means managing a mix of challenges that can affect movement, muscle tone, learning, speech, and sometimes hearing, seizures, or feeding, so daily life may involve therapies, specialist visits, and extra support with communication, mobility, or self-care. The condition can vary widely from one person to another, but for many living with SLC39A8-CDG, routines need to be carefully planned around energy, safety, and developmental needs. This also shapes life for parents, siblings, and other caregivers, who often take on a large role in appointments, advocacy, and day-to-day care, while adapting family routines to make space for both medical needs and ordinary moments of childhood and family life.
Treatment and drugs
Treatment for SLC39A8-CDG usually focuses on replacing what the body is missing and managing the problems it causes in daily life, such as movement difficulties, low muscle tone, seizures, feeding trouble, or delays in speech and learning. In many people with SLC39A8-CDG, doctors may prescribe manganese by mouth and then monitor blood levels closely, since the right dose matters and too much can be harmful. Treatment plans often combine several approaches, including physical, occupational, and speech therapy, along with medicines or nutrition support if seizures, muscle stiffness, or poor growth are part of the condition. Because this disorder can affect each person differently, the best treatment for SLC39A8-CDG is usually individualized and followed by a metabolic or genetics team over time.
Can you cure Slc39a8-cdg?
No, SLC39A8-CDG cannot currently be cured. Treatment is aimed at helping with day-to-day problems and may include physical, occupational, and speech therapy, care for seizures or movement problems, and close follow-up with specialists. Because this condition can cause very low manganese levels in some people, manganese supplements may help improve certain symptoms and body functions, especially if started early, but they do not remove the condition itself.
Non-drug treatment
Daily care for people with SLC39A8-CDG often focuses on improving movement, communication, feeding, and learning rather than on a single treatment. Because this condition can affect the brain, muscles, growth, and several organs, non-drug support is usually tailored to the problems each child or adult is facing. For many, treatment begins not at the pharmacy, but with therapies and practical supports that make day-to-day life safer and easier. Not every approach works the same way, so care plans are usually adjusted over time.
Physical therapy can help with low muscle tone, balance, stiffness, and delayed motor skills in people with SLC39A8-CDG. It often uses guided play, stretching, strengthening, and gait practice to support sitting, standing, and walking.
Occupational therapy focuses on everyday skills such as reaching, grasping, dressing, bathing, and using hands well. Some may find that simple changes at home, seating support, or adaptive tools make daily tasks less tiring and safer.
Speech and language therapy can support communication, understanding, and safe swallowing. For children with limited speech or early symptoms of SLC39A8-CDG that affect feeding and mouth control, therapists may also suggest picture boards or speech devices.
Feeding therapy and dietitian support can help when chewing, swallowing, poor weight gain, or long mealtimes are a problem. Texture changes, positioning during meals, and high-calorie nutrition plans may lower stress around eating and support growth.
Your genes may have an impact on how drugs work for you
For people living with SLC39A8-CDG, there is not yet strong, well-established evidence that this condition changes how most routine medicines work in a predictable, gene-based way. In day-to-day care, doctors usually choose medicines based on the person’s symptoms, age, and overall health, and they may watch more closely for side effects if there are problems such as seizures, muscle stiffness, or liver involvement. Genetic testing is mainly helpful for confirming the condition and guiding overall treatment, rather than for picking standard medicines based on how the body is expected to process them.
Pharmacological treatments
For many living with SLC39A8-CDG, treatment focuses on replacing manganese and easing day-to-day symptoms such as seizures or movement problems. The main disease-targeted medicine is oral manganese, usually manganese sulfate, and some specialists also use oral galactose to help improve abnormal glycosylation. There is no single medicine that cures SLC39A8-CDG, so treatment is usually tailored to the symptoms and lab results. Not everyone responds to the same medication in the same way.
Oral manganese sulfate is the best-known targeted treatment for SLC39A8-CDG because it can raise low manganese levels and improve some body processes affected by the disorder. In some children, it has helped blood test changes, growth, movement, and development, but it needs close specialist monitoring because too much manganese can be harmful.
Oral galactose is sometimes added to treatment for SLC39A8-CDG to support glycosylation, which is one of the main biochemical problems in this condition. It is usually used as an add-on rather than a replacement for manganese, and benefits can vary from one person to another.
If SLC39A8-CDG causes seizures, doctors may use standard anti-seizure drugs such as levetiracetam, valproate, or clobazam, chosen around the seizure type and the person’s age. This part of treatment for SLC39A8-CDG does not correct the underlying cause, but it can lower seizure frequency and improve safety.
Some people with SLC39A8-CDG need symptom-based drugs for stiffness, dystonia, or other movement problems, such as baclofen or trihexyphenidyl. If one option isn’t effective, second-line or alternative drugs may be offered, but response is individualized and these medicines are not helpful for everyone.
Genetic influences
The genetic cause of SLC39A8-CDG is well established: it happens when someone inherits disease-causing changes in both copies of the SLC39A8 gene, one from each parent. This gene helps move the mineral manganese into cells, and when it does not work properly, many body processes can be affected, including growth, brain development, and the way proteins are processed. SLC39A8-CDG is inherited in an autosomal recessive pattern, which means parents usually carry one changed copy each and often do not have symptoms themselves. Even with the same gene change, people can have different symptoms and different levels of severity, so the genetic result does not always predict exactly how SLC39A8-CDG will affect daily life. Genetic testing for SLC39A8-CDG can confirm the diagnosis and help families understand the chance of it happening again in another pregnancy.
Is Slc39a8-cdg genetic?
Genetics are central to Slc39a8-cdg, because it is caused by changes in the SLC39A8 gene. These genetic variations affect how the body handles manganese, and the exact change can influence how severe Slc39a8-cdg is.
Having a genetic risk is not necessarily a diagnosis
Differences in genes are a normal and common part of human biology. Most genetic variants do not directly affect health and are simply part of natural human diversity. For many genes, having a variant linked to a condition suggests a possible connection rather than a definite diagnosis, especially when several genes and environmental factors are involved. In some situations, though, a single well-studied variant in a specific gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
For many living with SLC39A8-CDG, treatment is shaped by the fact that the condition disrupts how the body handles manganese, a trace mineral that the brain and many enzymes need to work properly. Alongside medical history and lab results, genetic testing for SLC39A8-CDG can confirm a change in the SLC39A8 gene, which helps explain why manganese does not move into cells as it should. That matters because carefully supervised manganese supplementation can help some people, sometimes improving blood test results and, in some cases, movement, muscle tone, or development. The exact gene change, how severe the deficiency is, and how early treatment starts can all affect how much benefit someone sees. Doctors usually monitor treatment for SLC39A8-CDG closely, because too little manganese is harmful but too much can also cause problems. Medicines used for seizures, movement symptoms, or other day-to-day issues are still chosen mainly by symptoms, but the genetic result helps the care team decide whether targeted treatment for SLC39A8-CDG may help.
Interactions with other conditions
Day to day, people with SLC39A8-CDG may be affected by more than the condition itself, especially if they also have epilepsy, feeding problems, or repeated chest infections. Doctors call it a comorbidity when two conditions occur together. In SLC39A8-CDG, low muscle tone and trouble swallowing can make reflux or food going down the wrong way more likely, which in turn can raise the risk of lung irritation or pneumonia. Some may also have movement problems or developmental difficulties that overlap with conditions such as cerebral palsy or autism, but the underlying cause is different, so treatment planning needs to take the full picture into account. If seizures are present, illness, poor sleep, or dehydration can sometimes make them harder to control, and medicines used for one problem may affect another. Because early symptoms of SLC39A8-CDG can resemble several neurologic or metabolic disorders, careful follow-up with a team that understands the condition can help sort out what belongs to SLC39A8-CDG and what may need separate treatment.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Slc39a8-cdg?
Slc39a8-cdg can look similar to other rare inherited conditions, especially other congenital disorders of glycosylation, which are problems with how the body modifies proteins so they work properly. Doctors may also consider mitochondrial disorders, which affect how cells make energy, and movement conditions such as cerebral palsy, because low muscle tone, developmental delay, seizures, and unusual movements can overlap.
History
For many families, the history of this condition begins long before there was a name for it. Babies and children were described as having a mix of developmental delays, low muscle tone, movement problems, seizures, or poor growth, but these findings did not always point to one clear diagnosis. Some children were first thought to have a more common neurologic or metabolic condition, simply because the full pattern was not yet recognized.
As medical science evolved, doctors began to see that a small group of children shared a similar combination of symptoms and unusual laboratory findings. This led researchers to place the condition within a broader group called congenital disorders of glycosylation, or CDG, which are conditions that affect how the body modifies many proteins. Over time, Slc39a8-cdg came to be recognized as a distinct form within that group, and this helped make diagnosis more accurate.
The understanding of Slc39a8-cdg changed further when researchers later identified an underlying genetic cause and linked it to problems handling manganese, a mineral the body needs in very small amounts. That discovery mattered in everyday care, because it helped explain why symptoms can affect several parts of the body at once, including the brain, muscles, bones, and growth. It also showed why early symptoms of Slc39a8-cdg can look different from one child to another, which had made the condition easy to miss in the past.
In recent decades, awareness has grown as more case reports and lab studies have been published. Not every early description was complete, but together they helped build the picture doctors use today. This history is especially important for families, because a condition once recognized only after a long diagnostic search is now more likely to be considered earlier, especially in children with developmental concerns, movement symptoms, and signs of a CDG on testing.